A Phase 4 interventional study of cenegermin-bkbj in Neurotrophic Keratitis, sponsored by Dompé Farmaceutici S.p.A. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Dompé Farmaceutici S.p.A · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Corneal Diseases with a site in United States — 12 open to participants now, 13 under way, 3 of them phase 3. Corneal Diseases · United States.
Among the 76 studies in Corneal Diseases with a site in United States, this one is the 36th largest by enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2020, is one of 5 in phase 4, and was the 54th registered.
219 studies on the registry are indexed under Corneal Diseases; 43 are open to participants now.
Browse Corneal Diseases studies →12 of the 76 studies in Corneal Diseases with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 20–79 · Healthy volunteers
University of Maryland, Baltimore · Sites in United States
Ages 18+ · Healthy volunteers
Woolfson Eye Institute · Sites in United States
Ages 8+
Duke University · Sites in United States
Ages 18+
Optos, PLC · Sites in United States
Ages 22+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Corneal Diseases studies recruiting now, 21 (64%) set no upper age limit and 5 (15%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 14 · Phase 4 5
First in 1992; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is close to the median of 40 across 132 interventional studies indexed under Corneal Diseases.
Median enrollment 79 across the 54 interventional studies, 90 across the 22 observational. Of the 54 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 76 have an industry lead sponsor. The 10 most frequent:
Dompé Farmaceutici S.p.A is the lead sponsor of 52 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 18 (100%) have results posted.
Dompé Farmaceutici S.p.A has 1 study filed under Corneal Diseases — fewer than ten, so there is no comparison to draw.
6 of the studies in Corneal Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06993597University of Maryland, BaltimoreStudy of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy | 2027-03 |
| NCT03030755The Cleveland ClinicCorneal Elastography and Patient Specific Modeling | 2027-05 |
| NCT06854393Henry M. Jackson Foundation for the Advancement of Military MedicineLacripep for Corneal Wound Healing Study | 2027-06 |
| NCT04439552Boston Children's HospitalfMRI and IVCM Cornea Microscopy of CXL in Keratoconus | 2027-08 |
| NCT07780890Massachusetts General HospitalA Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases | 2027-09-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Corneal Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety and efficacy of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
This is a 8-week, multicenter, open label, prospective study with 24 weeks of follow-up to evaluate safety and efficacy of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
cenegermin-bkbj ophtalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks
Drug: cenegermin-bkbj
OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution administered as one drop in the affected eye(s), 6 times a day at 2-hour intervals for 8 weeks, in patients with Stage 1 neurotrophic keratitis.
Also known as: OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution
Corneal Epithelial Healing
Percentage of patients who experienced corneal epithelial healing. Corneal epithelial healing was defined by the central reading center as the absence of persistent epithelial staining abnormalities related to disease.
Time frame: Week 8
| Milestone | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj |
|---|---|
| Started | 37 |
| Completed | 29 |
| Not completed | 8 |
Percentage of patients who experienced corneal epithelial healing. Corneal epithelial healing was defined by the central reading center as the absence of persistent epithelial staining abnormalities related to disease.
| Participants | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj |
|---|---|
| No | 5 |
| Yes | 28 |
Collected over 34 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Study Eye | 0/37 (0%) | 1/37 (2.7%) | 22/37 (59.5%) |
| OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Non Study Eye | 0/37 (0%) | 0/37 (0%) | 13/37 (35.1%) |
| OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Systemic | 1/37 (2.7%) | 7/37 (18.9%) | 16/37 (43.2%) |
| Event | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Study Eye | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Non Study Eye | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Systemic |
|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/37 | 0/37 | 1/37 |
| COVID-19Infections and infestations | 0/37 | 0/37 | 1/37 |
| SyncopeNervous system disorders | 0/37 | 0/37 | 1/37 |
| Hiatus HerniaGastrointestinal disorders | 0/37 | 0/37 | 1/37 |
| Incarcerated parastomal herniaInjury, poisoning and procedural complications | 0/37 | 0/37 | 1/37 |
| Pneumonia bacterialInfections and infestations | 0/37 | 0/37 | 1/37 |
| Deep Vein ThrombosisVascular disorders | 0/37 | 0/37 | 1/37 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/37 | 0/37 | 1/37 |
| IridocyclitisEye disorders | 1/37 | 0/37 | 0/37 |
| Intestinal HaemorrhageGastrointestinal disorders | 0/37 | 0/37 | 1/37 |
| Event | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Study Eye | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Non Study Eye | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj - Systemic |
|---|---|---|---|
| Eye PainEye disorders | 14/37 | 2/37 | 0/37 |
| Vision blurredEye disorders | 7/37 | 3/37 | 0/37 |
| Dry EyeEye disorders | 4/37 | 2/37 | 0/37 |
| Foreign body sensation in eyesEye disorders | 4/37 | 0/37 | 0/37 |
| Eye irritationEye disorders | 3/37 | 2/37 | 0/37 |
| Eyelid painEye disorders | 3/37 | 2/37 | 0/37 |
| Burning sensationNervous system disorders | 3/37 | 1/37 | 0/37 |
| Corneal DystrophyCongenital, familial and genetic disorders | 2/37 | 1/37 | 0/37 |
| Conjunctival hyperaemiaEye disorders | 2/37 | 1/37 | 0/37 |
| Corneal OedemaEye disorders | 2/37 | 1/37 | 0/37 |
| Age, Categorical(Participants) | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 19 |
| >=65 years | 18 |
| Age, Continuous(years) | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj |
|---|---|
| Mean | 64.6 ± 11.89 |
| Sex: Female, Male(Participants) | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj |
|---|---|
| Female | 28 |
| Male | 9 |
| Ethnicity (NIH/OMB)(Participants) | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 35 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj |
|---|---|
| Race — White | 32 |
| Race — Black or African American | 3 |
| Race — Asian | 1 |
| Race — Other | 1 |
| Region of Enrollment(participants) | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj |
|---|---|
| United States | 37 |
| Treated Eyes(participants) | OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj |
|---|---|
| Participants with Treated Study Eye | 37 |
| Participants with Treated Non-Study Eye | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Sep 2021, 12 months.
Results were first posted in Jun 2023, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cenegermin